- Internship - UT Southwestern Medical Center (1993-1994), Internal Medicine
- Residency - UT Southwestern Medical Center (1994-1996), Internal Medicine
- Medical School - University of Chicago Pritzker School of Medicine (1989-1993)
- Fellowship - Vanderbilt University Medical Center (1997-2000), Hematology Oncology
Jonathan Dowell, M.D.
Associate Program Director, Hematology Oncology Fellowship Program
- Internal Medicine - Hematology/Oncology
- Medical Treatment of Lung Cancer
- Chest Cancers
Dr. Dowell completed his medical school education at the University of Chicago and received his internal medicine training at UT Southwestern. He then pursued his fellowship in Hematology and Oncology at Vanderbilt University, where he received extensive mentorship in thoracic malignancies from leaders in that field. Following fellowship, given his affinity for the clinical, research, and teaching environment at UT Southwestern, Dr. Dowell returned to join the faculty. Dr. Dowell specializes primarily in thoracic malignancies, including but not limited to non-small cell and small cell lung cancers, mesothelioma, and thymoma. He is also an active investigator in the clinical research program for these cancers at UT Southwestern. Dr. Dowell's approach is to educate patients and their families about their illness so that they can make informed treatment decisions. In addition, Dr. Dowell is devoted to medical education.
In 2018, he was named a Super Doctor by Texas Monthly.
His interests outside of work include travel, baseball, and family activities.
- American Society of Clinical Oncology
- American Society of Hematology
- Internal Medicine, Core Clerkship Teaching Award 2012, Teaching Award
- Eugene P. Frenkel Outstanding Teaching Award 2010, Teaching Award
- ASCO 2000, Merit Award
- Vanderbilt Hematology/Oncology 1998, Fellow Award
Upper Extremity Venous Thrombosis in Patients With Cancer With Peripherally Inserted Central Venous Catheters: A Retrospective Analysis of Risk Factors
Ahn DH, Illum HB, Wang DH, Sharma A, and Dowell JE Journal of Oncology Practice 2013 5
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
Dowell JE, Dunphy FR, Taub RN, Gerber DE, Ngov L, Yan J, Xie Y, Kindler HL Lung cancer (Amsterdam, Netherlands) 2012 Sep 77 3 567-71
Consent timing and experience: modifiable factors that may influence interest in clinical research.
Gerber DE, Rasco DW, Skinner CS, Dowell JE, Yan J, Sayne JR, Xie Y Journal of oncology practice / American Society of Clinical Oncology 2012 Mar 8 2 91-6
Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapy.
Gerber DE, Rasco DW, Le P, Yan J, Dowell JE, Xie Y Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011 Feb 6 2 365-71
ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation.
Hayes M, Lan C, Yan J, Xie Y, Gray T, Amirkhan RH, Dowell JE Anticancer research 2011 Dec 31 12 4135-9
Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population.
Rasco DW, Yan J, Xie Y, Dowell JE, Gerber DE Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010 Oct 5 10 1529-35
Small cell lung cancer: are we making progress?
Dowell JE The American journal of the medical sciences 2010 Jan 339 1 68-76
The impact of consenter characteristics and experience on patient interest in clinical research.
Rasco DW, Xie Y, Yan J, Sayne JR, Skinner CS, Dowell JE, Gerber DE The oncologist 2009 May 14 5 468-75
Small-cell lung cancer: translational research enroute to therapeutic advances.
Dowell J, Minna JD Oncology (Williston Park, N.Y.) 2008 Nov 22 13 1493, 1495
Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer.
Dudek AZ, Larson T, McCleod MJ, Schneider DJ, Dowell JE, Banerjee TK, Pandya KJ, Bromund JL, Chen R, Monberg MJ, Obasaju CK Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008 Apr 3 4 394-9
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.
Lewis LD, Miller AA, Rosner GL, Dowell JE, Valdivieso M, Relling MV, Egorin MJ, Bies RR, Hollis DR, Levine EG, Otterson GA, Millard F, Ratain MJ Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Jun 13 11 3302-11
- Upper Extremity Venous Thrombosis in Patients With Cancer With Peripherally Inserted Central Venous Catheters: A Retrospective Analysis of Risk Factors
- Medical Treatment of Lung Cancer
- Chest Cancers
- Lung Cancer
Showing 1 locations